Axol Bioscience Ltd.

Axol Bioscience Ltd. The Best Human Cell Culture Systems for Research Success Contact Axol Bioscience today! www.axolbio.com

Axol offer ready-made, well-characterized stem and functional cells complete with easy-to-understand protocols and video guides for handling them. We are devoted to making high quality, data-rich cellular products that are affordable for all research labs including starting up labs! We believe that all research labs should have easy access to the cells generated using the reprogramming and downstream differentiation technologies.

Modeling ALS with iPSC-derived motor neurons, microglia and astrocytesALS involves interactions between motor neurons an...
18/06/2026

Modeling ALS with iPSC-derived motor neurons, microglia and astrocytes

ALS involves interactions between motor neurons and glial cells, including astrocytes and microglia. To better capture this biology, we developed a human iPSC-derived tri-culture system incorporating motor neurons, astrocytes, and microglia.

Key observations

· Tri-culture provides a more representative in vitro model: motor neurons were co-cultured with astrocytes and microglia to establish a more physiologically relevant system
· Glial cells modulate neuronal activity: the addition of astrocytes and microglia alters firing frequency and synchronisation of motor neurons
· Microglia in the tri-culture system: incorporation of microglia as part of the tri-culture enables investigation of neuroinflammatory contributions within a multicellular environment
· Timing of glial integration impacts network behavior: earlier addition of astrocytes and microglia results in earlier increases in burst amplitude, indicating temporal effects on neuronal maturation
· ALS-associated phenotypes: iPSC-derived motor neurons from ALS donors show increased burst rate and reduced synchronisation, consistent with a hyperexcitable phenotype

This work highlights the importance of studying motor neurons alongside astrocytes and microglia in tri-culture systems to better reflect ALS-relevant cellular interactions.

Download the poster: https://hubs.la/Q04lRwgp0

Explore our iPSC-derived microglia: https://hubs.la/Q04lRRSJ0

Neuroinflammation is increasingly recognized as a key contributor to neurodegenerative diseases, with microglia playing ...
17/06/2026

Neuroinflammation is increasingly recognized as a key contributor to neurodegenerative diseases, with microglia playing a central role in shaping disease onset and progression.
A recent review by Kim, Kondo, and Inoue highlights how human iPSC-derived microglia are advancing our understanding of these processes.

Key insights

· Microglia are dynamic and heterogeneous, existing across a spectrum of functional states
· Disease-associated microglial phenotypes are linked to neuroinflammation and protein aggregation
· Many genetic risk factors for neurodegeneration are enriched in microglia-related pathways
· iPSC-derived microglia recapitulate key aspects of human microglial biology
· Enable the study of human-specific mechanisms in neurodegeneration

Why this matters:

iPSC-derived microglia provide a unique opportunity to study neuroinflammatory mechanisms in a human-relevant system. They enable the study of microglial state transitions, disease-associated phenotypes, and cell-cell interactions - bridging mechanistic insights with clinical translation.

Read the full paper: https://hubs.la/Q04lGTLd0

At Axol Bioscience, we support neurodegeneration research with human iPSC-derived microglia and co-culture systems, enabling the study of neuroinflammatory responses and disease-relevant phenotypes.

Patient-derived microglia models for ALS, FTD, HD, and AD are available on request through custom differentiation services. We also offer cytokine profiling, co-culture approaches, and aggregation-focused or bait labeling studies as tailored service projects.

Our poster highlighting cytokine profiling in iPSC-derived microglia models is available here: https://hubs.la/Q04lGZKG0

For more information or to access these models, contact [email protected]

We'll be at BIO International Convention, 22-25 June, San Diego, CAOur Chief Business Officer, Catherine Elton, and CEO,...
12/06/2026

We'll be at BIO International Convention, 22-25 June, San Diego, CA

Our Chief Business Officer, Catherine Elton, and CEO, Liam Taylor, will be attending as part of the Scottish Development International delegation and are looking forward to connecting with leaders from across the global biotech community.

BIO is where the industry comes together around a shared purpose: the drive to solve the impossible, push boundaries, and achieve better outcomes for patients, public health, and the world. This event offers an opportunity to reconnect with that purpose, recharge our commitment, and remember that behind every innovation lies a common mission: to improve lives.

At Axol Bioscience, we’re proud to support the development of more predictive, physiologically relevant models using our curated portfolio of 100+ patient and control iPSC lines, built over the past decade to accelerate translational research.

From neurodegenerative diseases such as Huntington’s, ALS/MND and Alzheimer’s, to rare and retinal disorders, our iPSC-derived models and services are helping enable more physiologically relevant research and discovery.

If you’d like to connect with Catherine and Liam in San Diego, please email [email protected], reach out via the BIO partnering platform, or meet us at the UK BIO Pavilion (Booth 2221).

We'll be at EUROoCS 2026 Annual Meeting, 22-24 June, Braga, PortugalOur Scientific Account Manager, Yanis Kasioulis, wil...
11/06/2026

We'll be at EUROoCS 2026 Annual Meeting, 22-24 June, Braga, Portugal

Our Scientific Account Manager, Yanis Kasioulis, will be there and looking forward to connecting with leaders from across the NAMs community.

The EUROoCS 2026 Annual Meeting will bring together experts from academia, clinical research, industry, regulatory agencies, and policymakers to explore the latest breakthroughs in organs-on-chip and microphysiological systems (MPS). Over two and a half days, the conference will feature plenary and keynote lectures, scientific sessions, poster presentations, and industry showcases, providing ample opportunities for interdisciplinary networking and exchange. Topics will include disease and multi-organ models, organ-on-chip, PK/PD modeling, biofabrication and biomaterials, standardization and toxicity, among others.

Yanis will be presenting on Monday, 22 June, during the 10:30 – 12:30 NATworks: Mapping the global Landscape of NAMs session, where he will discuss our physiologically relevant human iPSC models and their growing role in advancing next-generation NAMs.

If you are attending, make sure you say hello to Yanis.

Download our latest iPSCs and NAMs technology journal: https://hubs.la/Q04l0Qsy0

We'll be at Drug Discovery Europe 2026, 15-16 June, in BerlinOur Scientific Account Manager, Gizem Inak, and our CEO, Li...
11/06/2026

We'll be at Drug Discovery Europe 2026, 15-16 June, in Berlin

Our Scientific Account Manager, Gizem Inak, and our CEO, Liam Taylor will be at Drug Discovery Europe and ready to connect with scientists and leaders in drug discovery.

This year’s programme brings together key tracks covering target identification & validation, automation and AI-driven labs, computational chemistry, and advanced in vitro models and organoids, designed to foster both deep expertise and cross-disciplinary collaboration.

At Axol Bioscience, we support these workflows with more predictive, physiologically relevant iPSC-based models, helping bridge early discovery and translational research. This enables researchers to better model complex biology across neurodegenerative, cardiovascular and retinal diseases.

If you are attending, make sure you say hello to Gizem and Liam.

Learn more about us: http://www.axolbio.com

Huntington’s disease (HD) is characterized by the progressive loss of striatal medium spiny neurons, yet effective regen...
10/06/2026

Huntington’s disease (HD) is characterized by the progressive loss of striatal medium spiny neurons, yet effective regenerative strategies remain limited. However, encouraging progress is emerging toward clinically relevant iPSC-based therapeutic approaches.

A recent study by Jeon, Song et al. highlights the potential of iPSC-derived neuronal replacement as a viable therapeutic strategy for HD. This marks encouraging progress toward clinically relevant iPSC-based therapeutic approaches.

Key findings

· Clinical-grade iPSC-derived NPCs survived 12 weeks post-transplantation
· Differentiated into DARPP32+ GABAergic neurons
· Structural integration into host circuitry with axonal projections to the global pallidius
· Demonstrated sustained improvements in motor function
· Reduced neurodegeneration and inflammatory responses

Why this matters:

iPSC-derived models are increasingly critical not only for enabling regenerative strategies but also for studying disease mechanisms in a human-relevant system. They allow investigation of CAG repeat biology, aggregation phenotypes, and neuronal dysfunction, helping bridge the gap between mechanistic insight and clinical translation.
Read the full paper: https://hubs.ly/Q04kLNbC0

At Axol Bioscience, we support HD research with patient iPSC-derived neuronal and glial models. Using these systems, we have explored aggregation-related processes, CAG repeat expansion, and neuronal health and functionality.

Download our poster on Huntington’s disease iPSC-derived striatal neurons with 143 CAG repeats: https://hubs.ly/Q04kQjH-0

To access patient-derived models, contact [email protected]

From neurodegenerative diseases such as Huntington’s, ALS/MND, and Alzheimer’s, to rare and retinal disorders, our iPSC-...
08/06/2026

From neurodegenerative diseases such as Huntington’s, ALS/MND, and Alzheimer’s, to rare and retinal disorders, our iPSC-derived models and services are helping enable more physiologically relevant research and discovery.

Our Chief Business Officer, Catherine Elton, will be exhibiting at the event and ready to connect with scientists and leaders in drug dicovery.

At Axol Bioscience, we’re proud to support the development of more predictive, physiologically relevant models using our curated portfolio of 100+ patient and control iPSC lines, built over the past decade to accelerate translational research.

From neurodegenerative diseases such as Huntington’s, ALS/MND and Alzheimer’s, to rare and retinal disorders, our iPSC-derived models and services are helping enable more physiologically relevant research and discovery.

Catherine will also be attending BIO International in San Diego as part of the Scottish Development International delegation.

If you’re attending ELRIG in Boston or BIO in San Diego, get in touch to arrange a meeting.

Learn more about us: https://hubs.ly/Q04k4HcF0

Hypertrophic cardiomyopathy: comprehensive insights into pathogenic genes and genotype-phenotype associationsThis review...
03/06/2026

Hypertrophic cardiomyopathy: comprehensive insights into pathogenic genes and genotype-phenotype associations

This review by Hao., L, Chen., X, and Bo., K discusses the current knowledge on hypertrophic cardiomyopathy (HCM) as a genetically heterogeneous disease driven primarily by sarcomeric gene mutations, especially MYH7 and MYBPC3, which account for the majority of genetically confirmed cases. It highlights that clinical presentation is highly variable and influenced by genotype, mutation type, and modifiers such as ethnicity, age, and s*x.

The authors emphasise that genotype-phenotype correlations are clinically important for risk stratification, early diagnosis, and family screening, although they remain incompletely defined due to variable penetrance and complex gene-environment interactions.

The review also highlights the facts of significant population-specific differences in genetic variants, phenotypes, and management practices, underscoring the need for tailored approaches.

Overall, it concludes that integrating genetic testing with clinical and imaging data is essential for advancing precision medicine, but challenges such as variant interpretation and heterogeneity must be addressed to optimise personalised management.

Read the full paper: https://hubs.la/Q04jY0jX0

At Axol Bioscience, we provide specialist iPSC reprogramming services from patient and unaffected donor-derived PBMCs and fibroblasts, enabling researchers to conduct impactful comparative preclinical studies on iPSC-derived cardiomyocytes. Contact us at [email protected]

Advancing sporadic Alzheimer's research through APOE stratificationMost Alzheimer's models don't reflect the genetic div...
29/05/2026

Advancing sporadic Alzheimer's research through APOE stratification

Most Alzheimer's models don't reflect the genetic diversity of patients. In partnership with StrataStem, we've developed a comprehensive collection of sporadic Alzheimer's disease (sAD) iPSC lines that enable patient-stratified, disease-relevant in vitro models, built for drug discovery and neurodegeneration research that reflects clinical reality.

Our Early Access axoCells™ cortical neuron kits are available to biotech, pharma, and research institutes. Built for research readiness, each kit includes cell type-relevant media, supplements, coating reagents, and an optimised protocol, so you can move efficiently from setup to physiologically relevant and functional endpoint assays. Neural stem cells are derived from clinically characterised sAD and control donors across multiple APOE genotypes, giving researchers the physiologically relevant human systems they need.

Key features

• Human iPSC-derived neural stem cells from clinically characterised sAD and control donors across multiple APOE genotypes
• Characterised for key cortical neuron markers: MAP2, TBR1, CTIP2, VGLUT, and TUJ1
• Ready-to-use cortical and striatal neuron kits, including cells, cell type-relevant media, supplements, coating reagents, and optimised protocol included
• Reliable, patient-derived models designed for global research access

Request early access or learn more: https://hubs.la/Q04h_Kqc0

We are at the MPS World Summit 2026 in Washington, DCOur Strategic Partnerships Manager, Stuart Prime, Scientific Accoun...
27/05/2026

We are at the MPS World Summit 2026 in Washington, DC

Our Strategic Partnerships Manager, Stuart Prime, Scientific Account Manager Yanis Kasioulis, R&D Ophthalmology Scientists Kevin Gillois, and CEO Liam Taylor are at booth #131 and ready to connect with new and existing partners working with NAMs, organoids, and microfluidic platforms.

Kevin will be presenting our new poster "Development of a human iPSC-derived retinal microphysiological co-culture system for dry age-related macular degeneration" today at 3:15-4:45 PM, poster number 237, abstract number 189.

We’re launching our latest Technology Journal, highlighting advances in human iPSC-derived models and New
Approach Methodologies (NAMs) for predictive, physiologically relevant research.

Key highlights

• Reproducible 3D engineered cardiac tissues with real-time contractility measurement and pharmacological responsiveness
• High-resolution neuronal network electrophysiology capturing maturation, connectivity, and modulation by excitatory and inhibitory compounds
• Functional ALS disease modeling revealing ion channel and neurotransmitter changes in patient-derived motor neurons
• Human cell-based atrial fibrillation modelling with physiologically relevant electrophysiological readouts
• Scalable high-throughput electrophysiology for cardiac ion channel and action potential analysis

Robust, reproducible, assay-ready systems supporting drug discovery and safety pharmacology.

Thank you to our collaborators who are working on breaking new ground in new approach methodologies.

Download the new journal: https://hubs.la/Q04h_GRD0

Contact us at [email protected].

Address

Cambridge
CB101XL

Alerts

Be the first to know and let us send you an email when Axol Bioscience Ltd. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Axol Bioscience Ltd.:

Featured

Share